Levosalbutamol sulfate API is classified as a beta-agonist medication. It operates by inducing relaxation and dilation of the air passages that lead to the lungs, so promoting easier breathing. Both COPD (chronic obstructive pulmonary disease) and asthma are managed using levosalbutamol as a treatment. Similar to other bronchodilators, it operates by inducing relaxation of the smooth muscle in the bronchial airways, thereby reducing or reversing an acute episode of dyspnea or respiratory distress.
Levosalbutamol functions by inducing relaxation in the smooth muscles of the entire respiratory system, including the trachea and the terminal bronchioles. Elevated levels of cyclic AMP are also linked to the suppression of mediator release from airway mast cells.
Comments